These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31352016)

  • 1. Accuracy of multi-parametric breast MR imaging for predicting pathological complete response of operable breast cancer prior to neoadjuvant systemic therapy.
    Tsukada H; Tsukada J; Schrading S; Strobel K; Okamoto T; Kuhl CK
    Magn Reson Imaging; 2019 Oct; 62():242-248. PubMed ID: 31352016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
    Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
    Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response.
    Santamaría G; Bargalló X; Ganau S; Alonso I; Muñoz M; Mollà M; Fernández PL; Prat A
    Eur J Radiol; 2019 Aug; 117():132-139. PubMed ID: 31307638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
    Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
    Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
    Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
    Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
    Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
    van der Noordaa MEM; van Duijnhoven FH; Loo CE; van Werkhoven E; van de Vijver KK; Wiersma T; Winter-Warnars HAO; Sonke GS; Vrancken Peeters MTFD
    Breast; 2018 Aug; 40():76-81. PubMed ID: 29698928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
    Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
    Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
    Youk JH; Son EJ; Chung J; Kim JA; Kim EK
    Eur Radiol; 2012 Aug; 22(8):1724-34. PubMed ID: 22527371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
    Moon HG; Han W; Ahn SK; Cho N; Moon WK; Im SA; Park IA; Noh DY
    Ann Surg; 2013 Jan; 257(1):133-7. PubMed ID: 22968080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
    Murphy C; Mukaro V; Tobler R; Asher R; Gibbs E; West L; Giuffre B; Baron-Hay S; Khasraw M
    Intern Med J; 2018 Jun; 48(6):699-705. PubMed ID: 28869790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
    Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
    Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial.
    Golshan M; Wong SM; Loibl S; Huober JB; O'Shaughnessy J; Rugo HS; Wolmark N; Ansell P; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
    Eur J Surg Oncol; 2020 Feb; 46(2):223-228. PubMed ID: 31606288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
    Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
    Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.